Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells

Toxicol Appl Pharmacol. 2020 Jan 15:387:114857. doi: 10.1016/j.taap.2019.114857. Epub 2019 Dec 16.

Abstract

The aim of this study was to investigate the mechanism of YM155 cytotoxicity in human chronic myeloid leukemia (CML) cells. YM155-induced apoptosis of human CML K562 cells was characterized by ROS-mediated p38 MAPK activation, mitochondrial depolarization, and survivin and MCL1 downregulation. Moreover, YM155-induced autophagy caused degradation of HuR mRNA and downregulation of HuR protein expression, which resulted in destabilized survivin and MCL1 mRNA. Interestingly, survivin and MCL1 suppression contributed to autophagy-mediated HuR mRNA destabilization in YM155-treated cells. Pretreatment with inhibitors of p38 MAPK or autophagy alleviated YM155-induced autophagy and apoptosis in K562 cells, as well as YM155-induced downregulation of HuR, survivin, and MCL1. Ectopic overexpression of HuR, survivin, or MCL1 attenuated the cytotoxic effect of YM155 on K562 cells. Conversely, YM155 sensitized K562 cells to ABT-199 (a BCL2 inhibitor), and circumvented K562 cell resistance to ABT-199 because of its inhibitory effect on survivin and MCL1 expression. Overall, our data indicate that YM155-induced apoptosis is mediated by inducing autophagic HuR mRNA degradation, and reveal the pathway responsible for YM155-induced downregulation of survivin and MCL1 in K562 cells. Our findings also indicate a similar pathway underlying YM155-induced death in human CML MEG-01 cells.

Keywords: Chronic myeloid leukemia; HuR; MCL1; Survivin; YM155.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Apoptosis / drug effects
  • Autophagy / drug effects
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Cell Proliferation / drug effects
  • Down-Regulation / drug effects
  • Drug Resistance, Neoplasm / drug effects
  • ELAV-Like Protein 1 / genetics
  • ELAV-Like Protein 1 / metabolism
  • Humans
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Myeloid Cell Leukemia Sequence 1 Protein / metabolism
  • Naphthoquinones / pharmacology*
  • Naphthoquinones / therapeutic use
  • RNA Stability / drug effects
  • RNA, Messenger / metabolism
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use
  • Survivin / metabolism

Substances

  • Antineoplastic Agents
  • BIRC5 protein, human
  • Bridged Bicyclo Compounds, Heterocyclic
  • ELAV-Like Protein 1
  • ELAVL1 protein, human
  • Imidazoles
  • MCL1 protein, human
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Naphthoquinones
  • RNA, Messenger
  • Sulfonamides
  • Survivin
  • venetoclax
  • sepantronium